International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer's disease
Tian, Mei (Fudan University)
Civelek, A. Cahid (Johns Hopkins Medicine)
Carrió, Ignasi (Institut d'Investigació Biomèdica Sant Pau)
Watanabe, Yasuyoshi (RIKEN Center for Biosystems Dynamics Research)
Kang, Keon Wook (Seoul National University College of Medicine)
Murakami, Koji (Juntendo University Hospital)
Garibotto, Valentina (Geneva University Hospitals (Suïssa))
Prior, John O. (Lausanne University Hospital)
Barthel, Henryk (Leipzig University Medical Center)
Zhou, Rui (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Hou, Haifeng (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Dou, Xiaofeng (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Jin, Chentao (The Second Affiliated Hospital of Zhejiang University School of Medicine)
Zuo, Chuantao (Fudan University)
Zhang, Hong (Zhejiang University)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18 F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18 F-flortaucipir PET imaging. A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18 F-flortaucipir PET imaging in Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. This international consensus and practice guideline will help to promote the standardized use of 18 F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Altres ; recerca ; Versió publicada
Subject:	18 F-flortaucipir ; Alzheimer's disease (AD) ; Positron emission tomography (PET) ; Brain imaging
Published in:	European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49 (january 2022) , p. 895-904, ISSN 1619-7089

DOI: 10.1007/s00259-021-05673-w
PMID: 34978595

10 p, 1021.0 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles